<DOC>
	<DOCNO>NCT01256411</DOCNO>
	<brief_summary>The purpose study ass long-term safety , tolerability efficacy LCZ696 .</brief_summary>
	<brief_title>A Long-term ( 12 Months ) Safety , Tolerability Efficacy Study LCZ696 Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients successfully complete protocol No . CLCZ696A2219 , judge study investigator , able continue current study . Ability communicate comply study requirement demonstrate good medication compliance CLCZ696A2219 . Patients complete CLCZ696A2219 . Presence significant protocol violation CLCZ696A2219 . Patients deem unable comply protocol investigator . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>LCZ696</keyword>
	<keyword>dual-acting</keyword>
	<keyword>neprilysin</keyword>
	<keyword>nep inhibitor</keyword>
	<keyword>vasopeptidase</keyword>
	<keyword>angiotensin receptor</keyword>
	<keyword>angiotensin receptor neprilysin inhibitor ( ARNi )</keyword>
</DOC>